Manufacturing and PEGylation of a dual-acting peptide for diabetes

European Journal of Organic Chemistry

Volumn , Issue 35, 2008, Pages 5936-5945

  Krüger, Jochen ^a   Minuth, Torsten ^a   Schröder, Werner ^a   Werwath, Jörn ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Fragment synthesis; Mixed phase synthesis; Peptides; Solid phase synthesis; Synthesis design

Indexed keywords

EID: 56749168209     PISSN: 1434193X     EISSN: 10990690     Source Type: Journal    
DOI: 10.1002/ejoc.200800722     Document Type: Article

References (34)

1. For recent reviews on GLP-1, see: a) A. P. Abhay, D. M. Ravichand, V. Seshayamma, C. P. Satish, Int. J. Endocrinol. Metab. 2006, 4, 151-166;
2. b) C. F. Deacon, Diabetes Obes. Metab. 2007, 9, 23-31;
3. c) F. Giorgino, L. Laviola, A. Leonardini, A. Natalicchio, Diabetes Res. Clin. Pr. 2006, 74, 152-155;
4. d) M. C. Mancini, A. Halpern, Expert Opin. Invest. Drugs 2006, 15, 897-915;
5. e) C. M. Rotella, L. Pala, E. Mannucci, J. Endocrinol. Invest. 2005, 28, 746-758.
6. a) T. H. Claus, C. Q. Pan, J. M. Buxton, L. Yang, J. C. Reynolds, N. Barucci, M. Burns, A. A. Ortiz, S. Roczniak, J. N. Livingston, K. B. Clairmont, J. P. Whelan, J. Endocrinol. 2007, 192, 371-380;
7. b) C. Q. Pan, J. M. Buxton, S. L. Yung, I. Tom, L. Yang, H. Chen, M. MacDougall, A. Bell, T. H. Claus, K. B. Clairmont, J. P. Whelan, J. Biol. Chem. 2006, 281, 12506-12515.
8. R. B. Merriefield, J. Am. Chem. Soc. 1963, 85, 2149.
9. a) See, for instance: N. L. Benoiton, Chemistry of Peptide Synthesis Sensors Update (Eds.: H. Baltes, W. Göpel, J. Hesse), CRC Press Taylor & Francis Group, Boca Raton, 2006 pp. 125-154;
10. b) M. Amblard, J.-A. Fehrentz, J. Martinez, G. Subra in Peptide Synthesis and Applications (Ed.: J. Howl), Humana Press, Totowa, New Jersey, 2005, pp. 3-25.
11. See, for instance: N. Sewald, H.-D. Jakubke in Peptides: Chemistry and Biology, Wiley-VCH, Weinheim, 2002, pp. 230 ff.
12. a) B. Riniker, A. Flörsheimer, H. Fretz, P. Sieber, B. Kamber, Tetrahedron 1993, 49, 9307-9320;
13. b) K. Barlos, D. Gatos, G. Papaphotiou, W. Schäfer, Liebigs Ann. Chem. Ann. Chem. 1993, 215-220;
14. c) B. L. Bray, Nat. Rev. Drug Discovery 2003, 2, 587-593;
15. d) E. Atherton, R. Berry, D. Simpkin, D. Wellings, C. Willis, J. A. Eriksen, S. Buoen, Innovation and Perspectives in Solid Phase Synthesis & Combinatorial Libraries: Peptides, Proteins and Nucleic Acids-Small Molecule Organic Chemistry Diversity, Collected Papers, International Symposium, 6th, York, United Kingdom, Aug. 31-Sept. 4 1999, 2001;
16. e) L. Andersson, L. Blomberg, M. Flegel, L. Lepsa, B. Nilsson, M. Verlander, Biopolymers 2000, 55, 227-250;
17. f) T. Bruckdorfer, O. Marder, F. Albericio, Curr. Pharm. Biotechnol. 2004, 5, 29-43.
18. S. B. H. Kent, Annu. Rev. Biochem. 1988, 57, 959.
19. S. Sakakibara, Biopolymers 1999, 51, 279-296.
20. 31 partially underwent side reactions during SPPS via a dehydroalanine intermediate, which was formed by S-trityl elimination. In particular, this undesired side reaction was found during treatment with base, for example, during piperidine-mediated Fmoc deprotection.
21. Fmoc-Cys(Trt)OtBu has been described previously: L. Chen, N. Fotouhi, D. Y. Jackson, J. Tilley, WO 00/63234, 2000.
22. a) K. R. West, K. D. Bake, O. Sijbren, Org. Lett. 2005, 7, 2615-2618;
23. b) A. E. Koziol, B. Szady, E. Masiukiewicz, B. Rzeszotarska, M. A. Broda, A. Malgorzata, Chem. Pharm. Bull. 2001, 49, 418-423.
24. E. Masiukiewicz, B. Rzeszotarska, Org. Prep. Proced. Int. 1999, 31, 571-572.
25. See, for instance: W. C. Chan, P. D. White in Fmoc Solid Phase Peptide Synthesis - A Practical Approach (Eds.: W. C. Chan, P. D. White), Oxford University Press, New York, 2000, pp. 41-74.
26. See, for instance a) S. Bräse, S. Dahmen in Handbook of Combinatorial Chemistry (Eds.: K. C. Nicolaou, R. Hanko, W. Hartwig), Wiley-VCH, Weinheim, 2002, pp. 59-169;
27. b) F. Z. Dörwald in Organic Synthesis on Solid Phase Wiley-VCH, Weinheim, 2000, pp. 33-131.
28. E. Kaiser, R. L. Colescott, C. D. Bossinger, P. I. Cook, Anal. Biochem. 1970, 34, 595.
29. See, for instance: K. Barlos, D. Gatos in Fmoc Solid Phase Peptide Synthesis - A Practical Approach (Eds.: W. C. Chan, P. D. White), Oxford University Press, New York, 2000, pp. 215-228.
30. The alkylation site has not yet been determined. We assume that Cys, Tyr or Trp are alkylated.
31. I. Tom, V. Lee, M. Dumas, M. Madanat, J. Ouyang, J. Severs, J. Andersen, J. M. Buxton, J. P. Whelan, AAPS Journal 2007, 9, 227-234. http://www.aapsj.org/articles/aapsj0902/aapsj0902025/aapsj0902025.pdf.
32. The yield includes the peptide content of the starting peptide (approx. 80%), which contains stabilizing salts and residual water. Additionally, the indicated weight is based on the peptide portion disregarding the PEG portion.
33. A portion of the toluene solution was evaporated to dryness, and the residue was analyzed (HPLC method B). Accordingly, the ester was formed with complete retention of the stereogenic centre (99.8%ee).
34. M. Mergler, J. P. Durieux, The Bachem Practice of SPPS, Bachem AG, 2000.